Relief for GSK as Tesaro’s Zejula hits the mark in ovarian cancerGlaxoSmithKline raised eyebrows last year when it paid $5.1 billion for Tesaro and its PARP inhibitor Zejula, amid Share XRelief for GSK as Tesaro’s Zejula hits the mark in ovarian cancerhttps://pharmaphorum.com/news/relief-for-gsk-as-tesaros-zejula-hits-the-mark-in-ovarian-cancer/
Tesaro stock rockets as rumours of Roche takeover aboundShares in US biotech Tesaro peaked this week amid speculation that Roche is making plans to buy it. Share XTesaro stock rockets as rumours of Roche takeover aboundhttps://pharmaphorum.com/news/tesaro-stock-rockets-roche-takeover-abound/
